phentermine has been researched along with Adverse Drug Event in 9 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed disproportionality analyses to detect cardiovascular safety signals with three antiobesity drugs recently approved for marketing: lorcaserin, naltrexone-bupropion, phentermine, and phentermine-topiramate." | 3.96 | The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. ( Gorelik, B; Gorelik, E; Hirsh-Raccah, B; Masarwa, R; Matok, I; Perlman, A, 2020) |
| " Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications." | 2.52 | Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015) |
| " However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin." | 2.50 | Tolerability and safety of the new anti-obesity medications. ( Aldhoon-Hainerová, I; Hainer, V, 2014) |
| " Receptorome screening has implicated N-deethylation of fenfluramine and serotonin 5-hydroxy-t-ryptamine 2B receptors in the adverse effects of the drug; subsequent studies corroborated this finding." | 2.43 | Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. ( Roth, BL; Setola, V, 2005) |
| "Phentermine is an internationally recognised amphetamine derivative with significant appetite-suppressing properties." | 1.91 | Potential drug-drug interactions with phentermine among long-term phentermine consumers: A retrospective analysis. ( Du Plessis, JM; Fourie, A; Julyan, M; Mostert, L, 2023) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Fourie, A | 1 |
| Julyan, M | 1 |
| Mostert, L | 1 |
| Du Plessis, JM | 1 |
| Gorelik, E | 1 |
| Gorelik, B | 1 |
| Masarwa, R | 1 |
| Perlman, A | 1 |
| Hirsh-Raccah, B | 1 |
| Matok, I | 1 |
| Hainer, V | 1 |
| Aldhoon-Hainerová, I | 1 |
| Fujioka, K | 1 |
| Setola, V | 1 |
| Roth, BL | 1 |
| Derby, LE | 1 |
| Myers, MW | 1 |
| Jick, H | 1 |
3 reviews available for phentermine and Adverse Drug Event
| Article | Year |
|---|---|
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related | 2014 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects | 2015 |
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
Topics: Animals; Appetite Depressants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Drug-Related S | 2005 |
6 other studies available for phentermine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Potential drug-drug interactions with phentermine among long-term phentermine consumers: A retrospective analysis.
Topics: Cross-Sectional Studies; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; | 2023 |
The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Obesity Agents; Benzazepines; Cardiovascu | 2020 |
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
Topics: Aged; Appetite Depressants; Body Mass Index; Case-Control Studies; Cerebrovascular Disorders; Cohort | 1999 |